Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Discussion of a new monoclonal antibody, ianalumab (previously known as VAY736), targeting the B-cell activating factor (BAFF) receptor. We refer to the compound as VAY736 for consistency with the interview and abstract for this article.
Dr. Mato and Dr. Woyach discusses the results of a study looking at which features might predict the future development of Richter’s syndrome in patients treated with ibrutinib.
At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Anthony Mato interviewed Dr. Jennifer Woyach. They discussed updated results from the Alliance A041202 trial, which now has longer-term follow-up data.
At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a tolerable level of adverse events (AE).
Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.
The usual approach with most venetoclax based therapies is a “one size fits all” with all patients stopping treatment after a fixed duration, such as after one or two years of venetoclax.
Ask the Pharmacist Question: I just listened to the multi dis perspective BTK inhibitors webinar. I thought I heard calcium channel blockers are contraindicated with ibrutinib. Wondering if this is true?
Ask the Doctor Question: I am 66 years old and diagnosed with CLL three-years ago. My WBC auto was 71.3 three-months ago, but now jumped to 178.1. My doctor is telling
Ask the Doctor Question: My husband is a CLL patient and on 5/12/2021 he started treatment with Ibrutinib. After two-months, today we were informed of his analytical results: WBC decreased from
One click to our most popular content.
